Carrie Brownstein

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure

Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi et al. · American Journal of Hematology · 2020 · 139 citations · Full text

Hematological Malignancy, Therapeutic Drug Monitoring, Stringent Criteria +15

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, David R. Spigel, David Chen et al. · Journal of Clinical Oncology · 2011 · 129 citations · Full text

Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages

Carrie Brownstein, Arunkumar B. Deora, Andrew T. Jacovina et al. · Blood · 2003 · 115 citations

Factors That Affect Final Height and Change in Height Standard Deviation Scores in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study

Carrie Brownstein, Ann Mertens, Pauline Mitby et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 74 citations · Full text

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher et al. · Clinical Cancer Research · 2015 · 68 citations